Innovative Research Awards Unveiled for Lung Cancer Treatments
Lung Cancer Research Foundation Announces Award Recipients
$1 Million in Research Grants Focused on Lung Cancers Harboring HER2 Mutations and/or Other HER2 Alterations Awarded.
New York - The Lung Cancer Research Foundation (LCRF), in collaboration with Bayer Pharmaceuticals, has announced the recipients of notable research grants aimed at advancing the understanding and treatment of lung cancers featuring HER2 mutations and various HER2 alterations.
Focus on HER2 Mutations in Lung Cancer
These grants are strategically directed toward innovative projects that tackle essential mechanistic questions and development of therapies across the care continuum for HER2-mutated non-small cell lung cancer (NSCLC) while potentially elevating patient outcomes. Named the LCRF|Bayer Research Award on Innovative Therapeutic Strategies to Treat Lung Cancers Harboring HER2 Mutations and/or Other HER2 Alterations, the submissions required robust, correlative translational research that furthers the understanding of HER2-driven lung cancers. Importantly, the grant applications also necessitated including a patient or patient advocate within the research team to collaborate on project design.
Significant Funding for Promising Research
The selected awardees will each receive $500,000 distributed over two years to support their research initiatives. "There is an urgent need to understand the role of HER2 alterations as oncogenic drivers and the mechanisms of tumor response and resistance," remarked Kathryn O'Donnell, PhD, chair of the Scientific Advisory Board of LCRF. "It is our hope that these grants will yield tangible benefits for patients whose tumors harbor these genetic mutations or alterations."
Congratulations to the Award Recipients
Lucia Regales, PhD, who serves as the Global Medical & Evidence Strategy Lead Oncology at Bayer’s Pharmaceuticals Division, stated, "We extend heartfelt congratulations to the award recipients. Our commitment aligns with that of these investigators, as we are dedicated to improving the lives of lung cancer patients and aspiring to deliver impactful research findings that enhance treatment options and overall quality of life."
Meet the Recipients of the Research Award
The award recipients of the LCRF|Bayer Research Award on Innovative Therapeutic Strategies to Treat Lung Cancers Harboring HER2 Mutations and/or Other HER2 Alterations are:
Dr. Sarah Goldberg, MD, MPH
Yale School of Medicine
Associate Professor of Internal Medicine (Medical Oncology)
Associate Director, Hematology/Oncology Fellowship Program
Research Director, Center for Thoracic Cancers
Stratifying and Personalizing for HER2 Mutated Lung Cancers
Dr. Xiuning Le, MD, PhD
University of Texas MD Anderson Cancer Center
Associate Professor, Department of Thoracic/Head and Neck Medical Oncology
Division of Internal Medicine
Characterization of HER2 Mutations' Sensitivity to Sevabertinib & Development of Novel Combination Strategies to Overcome Resistance to Current HER2 Therapies
About LCRF and Its Mission
The Lung Cancer Research Foundation is a leading nonprofit organization dedicated to funding groundbreaking, high-reward research that has the potential to extend survival and enhance the quality of life for individuals diagnosed with lung cancer. LCRF's mission revolves around improving lung cancer outcomes through investments in research focused on prevention, diagnosis, treatment, and ultimately, the cure of lung cancer. To date, LCRF has successfully funded 431 research grants totaling nearly $49 million, making it the largest nonprofit organization dedicated to lung cancer research funding initiatives.
For more information about LCRF and its funding programs, please visit lcrf.org.
Frequently Asked Questions
What is the LCRF|Bayer Research Award?
The LCRF|Bayer Research Award funds research aimed at understanding and treating lung cancers with HER2 mutations.
Who are the recipients of the recent research awards?
The recipients are Dr. Sarah Goldberg from Yale School of Medicine and Dr. Xiuning Le from MD Anderson Cancer Center.
What is the funding amount for each awarded project?
Each awarded project receives $500,000 over a span of two years.
What is the focus of the awarded research projects?
The projects focus on innovative strategies to address HER2 mutations in lung cancer and enhance treatment outcomes.
Where can I find more information about LCRF?
You can visit the official LCRF website at lcrf.org for detailed information about their mission and funded research.
About The Author
Contact Kelly Martin privately here. Or send an email with ATTN: Kelly Martin as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.